Platelet activation signaling proteins

Platelet activation signaling proteins represent a complex network of receptors and intracellular effectors that coordinate the platelet response to vascular damage (Source: PubMed, PMID: 29958137). This group includes G protein-coupled receptors (GPCRs) such as the P2Y12 and P2Y1 receptors for ADP, and PAR-1 and PAR-4 for thrombin (Source: StatPearls, NBK537132). Additionally, it encompasses enzymes like cyclooxygenase-1 (COX-1) and phosphodiesterases, as well as integrins like glycoprotein IIb/IIIa (αIIbβ3) (Source: UniProt, P08514). These proteins are critical for hemostasis but also drive pathological thrombosis in cardiovascular diseases such as myocardial infarction and stroke (Source: NIH, PMC3593730). Pharmacological modulation of these signaling proteins, through drugs like aspirin, clopidogrel, and vorapaxar, is a cornerstone of antiplatelet therapy to prevent ischemic events (Source: PubMed, PMID: 30217310). Activation of these pathways leads to calcium mobilization, shape change, and the release of granule contents, which further amplify the recruitment of additional platelets. Therapeutic strategies often involve dual antiplatelet therapy (DAPT) to target multiple signaling nodes simultaneously, thereby reducing the risk of stent thrombosis and recurrent myocardial infarction. However, the inhibition of these signaling proteins inherently carries a risk of bleeding complications, necessitating a careful balance between antithrombotic efficacy and safety.

Other names

Platelet activation pathwayPlatelet signaling cascadeHemostatic signaling proteins

Inhibition of cyclooxygenase-1, antagonism of P2Y12 purinergic receptors, blockade of glycoprotein IIb/IIIa receptors, and antagonism of protease-activated receptor-1.